海南海药：子公司注射用美罗培南通过仿制药一致性评价

Core Viewpoint - The company has received approval from the National Medical Products Administration for its subsidiary's injectable Meropenem, which is expected to enhance market competitiveness and positively impact the company's performance [1] Group 1: Regulatory Approval - The full-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has obtained the approval notice for the supplemental application of injectable Meropenem from the National Medical Products Administration [1] Group 2: Market Impact - The drug has passed the consistency evaluation, indicating that its quality and efficacy are equivalent to the original product, which will benefit the market competitiveness of the drug [1] - The approval is anticipated to have a positive effect on the company's performance [1]